Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
Some hydantoin derivatives have been explored for their potential as anticancer agents by inhibiting receptor tyrosine kinases (RTKs). Benzalhydantoin derivatives were obtained from a two-step reaction: condensation and alkylation reaction. The benzalhydantoin activities were obtained from the enzym...
| Main Authors: | Muhammad Naufal, Hidayat, Ika Wiani, Hermawati, Elvira, Syah, Yana Maolana, Al-Anshori, Jamaludin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Penerbit Universiti Kebangsaan Malaysia
2025
|
| Online Access: | http://journalarticle.ukm.my/25066/ http://journalarticle.ukm.my/25066/1/SSB%2016.pdf |
Similar Items
An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)
by: Gutteridge, Eleanor
Published: (2010)
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)
by: Carter, Joanne J., et al.
Published: (2016)
Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)
by: Marlow, Maria, et al.
Published: (2015)
Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)
by: Al-Ameedee, Mohammed
Published: (2017)
Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)
by: Chai, C.S., et al.
Published: (2017)
An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)
by: Kuruppu, Anchala I., et al.
Published: (2015)
EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)
Case Series of Small Cell Lung Cancer Transformation
as Resistance Mechanism to Epidermal Growth Factor
Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017)
by: Liam, C, et al.
Published: (2017)
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)
Real-time analysis of the binding of fluorescent VEGF₁₆₅a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
by: Kilpatrick, Laura E., et al.
Published: (2017)
by: Kilpatrick, Laura E., et al.
Published: (2017)
Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy
by: Chai, Chee She
Published: (2015)
by: Chai, Chee She
Published: (2015)
Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)
Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)
by: Chai, C.S., et al.
Published: (2017)
Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)
by: Md. Zahirul , Kabir
Published: (2018)
Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
by: Carter, Joanne J., et al.
Published: (2015)
by: Carter, Joanne J., et al.
Published: (2015)
Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017)
by: Chee, Shee Chai
Published: (2017)
In silico discovery of potential uridine-cytidine kinase 2 inhibitors form the rhizome of Alpina mutica
by: Malami, Ibrahim, et al.
Published: (2016)
by: Malami, Ibrahim, et al.
Published: (2016)
Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)
by: Ali, Zakiah Bakar
Published: (2024)
Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)
by: Carrim, N., et al.
Published: (2014)
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)
by: Yu, Yu, et al.
Published: (2015)
The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)
by: Canobbio, I., et al.
Published: (2015)
A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)
by: Clark, Richard E., et al.
Published: (2017)
The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)
by: Cipolla, L., et al.
Published: (2013)
Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis
by: Koh, Rhun Yian, et al.
Published: (2015)
by: Koh, Rhun Yian, et al.
Published: (2015)
Editorial: Platelet hem-Immunoreceptor Tyrosine-Based Activation Motif Receptors: At Lease One Required
by: Berndt, Michael, et al.
Published: (2013)
by: Berndt, Michael, et al.
Published: (2013)
A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)
by: Kuan, Jew-Win, et al.
Published: (2016)
Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2
by: Canobbio, I., et al.
Published: (2013)
by: Canobbio, I., et al.
Published: (2013)
In silico homology modelling and identification of Tousled-like kinase 1 inhibitors for glioblastoma therapy via high throughput virtual screening protein-ligand docking
by: Kamariah Ibrahim,, et al.
Published: (2018)
by: Kamariah Ibrahim,, et al.
Published: (2018)
In silico analysis, molecular modeling
and docking of pseudomonas
aeruginosa putative choline kinase
by: Almakfoukh, Abdonasr Mohamed Ali
Published: (2021)
by: Almakfoukh, Abdonasr Mohamed Ali
Published: (2021)
Src family tyrosine kinase Lyn mediates VWF GPIb-IX induced platelet activation via the cGMP signaling pathway
by: Yin, H., et al.
Published: (2008)
by: Yin, H., et al.
Published: (2008)
In silico study of carvone derivatives as potential neuraminidase inhibitors
by: Jusoh, Noorakmar, et al.
Published: (2018)
by: Jusoh, Noorakmar, et al.
Published: (2018)
In silico analysis, structural modelling and molecular docking of putative Klebsiella pneumoniae choline kinase
by: Albaskeni, Abdulrhman Mahmoud
Published: (2021)
by: Albaskeni, Abdulrhman Mahmoud
Published: (2021)
The tyrosine kinase Pyk2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha IIb beta 3
by: Guidetti, G., et al.
Published: (2011)
by: Guidetti, G., et al.
Published: (2011)
The tyrosine kinase PYK2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha iib beta 3
by: Guidetti, G., et al.
Published: (2011)
by: Guidetti, G., et al.
Published: (2011)
In vitro and in silico evaluations of diarylpentanoid series as a-glucosidase inhibitor
by: Leong, Sze Wei, et al.
Published: (2018)
by: Leong, Sze Wei, et al.
Published: (2018)
Evaluation of transcriptional cyclin dependent kinase inhibitors as potential cancer therapeutics
by: Liu, Xiangrui
Published: (2012)
by: Liu, Xiangrui
Published: (2012)
Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma
by: Abbhi, V., et al.
Published: (2017)
by: Abbhi, V., et al.
Published: (2017)
Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development
by: Falasca, Marco
Published: (2011)
by: Falasca, Marco
Published: (2011)
In silico analysis for discovery of dengue virus inhibitor from natural compounds
by: Roney, Miah, et al.
Published: (2022)
by: Roney, Miah, et al.
Published: (2022)
Activity of the aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia
by: Grundy, Martin
Published: (2012)
by: Grundy, Martin
Published: (2012)
Similar Items
-
An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010) -
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016) -
Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015) -
Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017) -
Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)